Clinical Trials
5 trialsNCT00747123 2024-10-03
A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma
Celgene
Phase 2 Completed
NCT01284348 2024-08-29
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT01190644 2023-11-29
Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00931606 2023-09-13
MK-7962-012
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT01736683 2022-10-24
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Merck Sharp & Dohme LLC
Phase 2 Completed